Article Text

PDF
FRI0080 Effects of IL-6 Receptor Inhibition Therapy on The Serum Levels of IL-33 and IL-6 in Patients with Rheumatoid Arthritis
  1. I.A. Choi1,
  2. S.J. Lee1,2,
  3. W. Park3,
  4. S.H. Park4,
  5. S.-C. Shim5,
  6. H.J. Baek6,
  7. D.-H. Yoo7,
  8. H.A. Kim8,
  9. S.K. Lee9,
  10. Y.J. Lee10,
  11. Y.E. Park11,
  12. H.-S. Cha12,
  13. E.Y. Lee1,
  14. E.B. Lee1,
  15. Y.W. Song1,2
  1. 1Division of Rheumatology, Seoul National University Hospital
  2. 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Center, Seoul National University, Seoul
  3. 3Division of Rheumatology, Inha University Hospital, Incheon
  4. 4Division of Rheumatology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul
  5. 5Division of Rheumatology, Eulji University Hospital, Daejeon
  6. 6Division of Rheumatology, Gachon University Gil Medical Center, Incheon
  7. 7Division of Rheumatology, Hanyang University Medical Center, Seoul
  8. 8Division of Rheumatology, Hallym University Medical Center, Anyang
  9. 9Division of Rheumatology, Yonsei University Health System, Seoul
  10. 10Division of Rheumatology, Seoul National University Bundang Hospital, Seongnam
  11. 11Division of Rheumatology, Pusan National University Hospital, Busan
  12. 12Division of Rheumatology, Sam Sung Medical Center, Seoul, Korea, Republic Of

Abstract

Background Several pro-inflammatory cytokines such as TNF-α, IL-1, IL-6, IL-8 and IL-15 are known to be critical in synovial inflammatory process in RA and successful results have been obtained in RA treatment with targeting pro-inflammatory cytokines including TNF-α, IL-1 and IL-6.

Objectives This study sought to investigate the role of IL-33 and IL-6 in RA patients receiving IL-6 receptor inhibition therapy.

Methods We analyzed the association of the IL-33 and IL-6 level with disease activity and serologic features in 83 patients with RA. We also measured the serum level of IL-33 and IL-6 before and after the administration of tocilizumab for 24 weeks in 40 patients.

Results Serum IL-33 level showed significant correlation with RF (rho =0.660, p<0.001) but did not correlate with DAS28, ESR, hsCRP or RA duration. IL-6 level was significantly correlated with hsCRP (rho =0.482, p<0.001) but not correlate with DAS28, ESR, RF or RA duration. There was no correlation between serum IL-6 and IL-33 levels.

Serum IL-33 level significantly decreased after 24 weeks of IL-6 receptor inhibition in patients with RA (p<0.001). When comparing subgroups according to ACR20 response, serum IL-33 levels were significantly decreased after 24 weeks of IL-6 receptor inhibition therapy in ACR20 responders (p<0.001) but not in the non-responders (p=0.084). Baseline IL-33 levels were not significantly different between the two subgroups (p=0.765).

Serum IL-6 levels were not significantly changed after 24 weeks of IL-6 receptor inhibition therapy (median 7.1 to 8.9 pg/mL, p=0.503). Changes of IL-6 levels were insignificant both in ACR20 responders and non-responders after 24 weeks of IL-6 receptor inhibition therapy. Baseline IL-6 levels were not different between ACR20 responders and non-responders.

Conclusions The use of IL-6 receptor inhibitor decreased the serum level of IL-33 and this effect seems to be led by the responder group. IL-33 could be a useful indicator to monitor the response in IL-6 receptor inhibition therapy.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.